A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh( αK): A phase I study.

CONCLUSION: The intranasal inactivated influenza vaccine is generally safe, and the LTh(αK)-adjuvanted vaccine is more immunogenic than non-adjuvanted control vaccine. ClinicalTrials.gov Identifier: NCT03293732. PMID: 30837170 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30837170?dopt=Abstract

Source: Vaccine - March 1, 2019 Category: Allergy & Immunology Authors: Pan SC, Hsieh SM, Lin CF, Hsu YS, Chang M, Chang SC Tags: Vaccine Source Type: research